APHEXDA motixafortide
Drug Class
CXCR4 antagonistCXCR4 拮抗剂
Mechanism
Inhibits CXCR4 binding to SDF-1alpha, mobilizing CD34+ hematopoietic stem cells from bone marrow to peripheral blood.抑制 CXCR4 与 SDF-1α 的结合，从而将 CD34+ 造血干细胞从骨髓动员至外周血中。
Approved Indication
In combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with multiple myeloma.联合菲格司亭 (G-CSF) 动员造血干细胞进入外周血，以在多发性骨髓瘤患者中进行采集并随后进行自体干细胞移植。
What This Means For Patients
APHEXDA (motixafortide) is a stem cell mobilization agent used for patients with multiple myeloma undergoing autologous stem cell transplantation. It helps release hematopoietic stem cells into the bloodstream for easier collection. It is clinically accessible in Boao Lecheng under Hainan's special-import policy.APHEXDA（莫替沙福肽）是一种干细胞动员剂，用于准备接受自体干细胞移植的多发性骨髓瘤患者。它有助于将造血干细胞释放到血流中以便进行收集。该药物已通过博鳌乐城特许进口政策引入使用。
Regulatory Approvals
- FDA — approved (2023) — label
Pivotal Clinical Evidence
- GENESIS — Crees et al., Nat Med 2023 (NCT03246529) — DOI
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.